靶向治疗已成为当今肿瘤研究领域的热点。抗体-药物偶联物(antibody drug conjugates,ADC)兼具抗体的高特异性和细胞毒药物对肿瘤的高毒性,代表了新一代抗体技术的发展方向。ADC由"弹头"药物(细胞毒药物)、抗体以及偶联抗体...靶向治疗已成为当今肿瘤研究领域的热点。抗体-药物偶联物(antibody drug conjugates,ADC)兼具抗体的高特异性和细胞毒药物对肿瘤的高毒性,代表了新一代抗体技术的发展方向。ADC由"弹头"药物(细胞毒药物)、抗体以及偶联抗体和药物的偶联链3部分组成。ADC利用抗体作为载体将"弹头"药物送至靶部位,并通过细胞内吞效应进入溶酶体,释放出细胞毒性药物,从而达到专一性杀死癌细胞而不损伤正常组织细胞的作用。本文综述近年来ADC研制和发展趋势,并探讨ADC研发过程中的几个可能的关键影响因素。展开更多
传统的癌症化疗常伴随着系统毒性,靶向治疗已成为当今肿瘤研究领域的热点。抗体-药物偶联物(antibody drug conjugates,ADCs)利用单克隆抗体(m ABs)对肿瘤细胞表面过表达抗原的特异性,将"弹头"药物(细胞毒药物)选择性地输送...传统的癌症化疗常伴随着系统毒性,靶向治疗已成为当今肿瘤研究领域的热点。抗体-药物偶联物(antibody drug conjugates,ADCs)利用单克隆抗体(m ABs)对肿瘤细胞表面过表达抗原的特异性,将"弹头"药物(细胞毒药物)选择性地输送到肿瘤细胞中以改善药物治疗窗。ADCs由"弹头"药物、抗体和药物的偶联链三个部分组成,其兼具了抗体的高特异性和细胞毒素的高活性。而随着抗体药物偶联物brentuximab vedotin(SGN-35,Adcetris)和trastuzumab emtansine(T-DM1,Kadcyla)的成功上市,ADCs引起了人们极大的关注。本文综述ADC的分子特征以及组分优化选择,并简单介绍ADC的发展历程。展开更多
It is in a great demand to design a biodegradable, tumor microenvironment-sensitive drug delivery system to achieve safe and highly efficacious treatment of cancer.Herein, a novel pH/enzyme sensitive dendritic pdi HPM...It is in a great demand to design a biodegradable, tumor microenvironment-sensitive drug delivery system to achieve safe and highly efficacious treatment of cancer.Herein, a novel pH/enzyme sensitive dendritic pdi HPMADOX conjugate was designed. di HPMA dendritic copolymer with GFLG segments in the branches which are sensitive to the intracellular enzyme of the tumor was prepared through RAFT polymerization. DOX was attached to dendritic di HPMA polymer through a pH-sensitive hydrazone bond. The dendritic pdi HPMA-DOX conjugate self-assembled into nanoparticles with an ideal spherical shape at a mean size of 103 nm. The DOX attached to the polymeric carrier was released in an acidic environment, and the GFLG linker for synthesizing the dendritic vehicle with a high molecular weight（M_W, 220 kDa） was cleaved to release low MWsegments（〈40 kDa） in the presence of cathepsin B. The dendritic polymeric conjugate was internalized via an endocytic pathway, and then released the anticancer drug, which led to significant cytotoxicity for tumors. The blood circulation time was profoundly prolonged, resulting in high accumulation of DOX into tumors. In vivo anti-tumor experiments with 4 T1 tumor bearing mice demonstrated that the conjugate had a better antitumor efficacy in comparison with free DOX. Additionally, body weight measurements and histological examinations indicated that the conjugate showed low toxicities to normal tissues. This dendritic polymeric drug carrier in a response to intracellular enzyme and acidic pH of tumor tissue or cells holds great promise in tumor-targeted therapy.展开更多
文摘靶向治疗已成为当今肿瘤研究领域的热点。抗体-药物偶联物(antibody drug conjugates,ADC)兼具抗体的高特异性和细胞毒药物对肿瘤的高毒性,代表了新一代抗体技术的发展方向。ADC由"弹头"药物(细胞毒药物)、抗体以及偶联抗体和药物的偶联链3部分组成。ADC利用抗体作为载体将"弹头"药物送至靶部位,并通过细胞内吞效应进入溶酶体,释放出细胞毒性药物,从而达到专一性杀死癌细胞而不损伤正常组织细胞的作用。本文综述近年来ADC研制和发展趋势,并探讨ADC研发过程中的几个可能的关键影响因素。
基金supported by the National Natural Science Foundation of China (51673127 and 8162103)International Science and Technology Cooperation Program of China (2015DFE52780 and 81220108013)International Science and Technology Cooperation Program of Chengdu (2016-GH03-00005-HZ)
文摘It is in a great demand to design a biodegradable, tumor microenvironment-sensitive drug delivery system to achieve safe and highly efficacious treatment of cancer.Herein, a novel pH/enzyme sensitive dendritic pdi HPMADOX conjugate was designed. di HPMA dendritic copolymer with GFLG segments in the branches which are sensitive to the intracellular enzyme of the tumor was prepared through RAFT polymerization. DOX was attached to dendritic di HPMA polymer through a pH-sensitive hydrazone bond. The dendritic pdi HPMA-DOX conjugate self-assembled into nanoparticles with an ideal spherical shape at a mean size of 103 nm. The DOX attached to the polymeric carrier was released in an acidic environment, and the GFLG linker for synthesizing the dendritic vehicle with a high molecular weight（M_W, 220 kDa） was cleaved to release low MWsegments（〈40 kDa） in the presence of cathepsin B. The dendritic polymeric conjugate was internalized via an endocytic pathway, and then released the anticancer drug, which led to significant cytotoxicity for tumors. The blood circulation time was profoundly prolonged, resulting in high accumulation of DOX into tumors. In vivo anti-tumor experiments with 4 T1 tumor bearing mice demonstrated that the conjugate had a better antitumor efficacy in comparison with free DOX. Additionally, body weight measurements and histological examinations indicated that the conjugate showed low toxicities to normal tissues. This dendritic polymeric drug carrier in a response to intracellular enzyme and acidic pH of tumor tissue or cells holds great promise in tumor-targeted therapy.
